{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:21:53Z","timestamp":1780489313676,"version":"3.54.1"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2016\/21\/D\/NZ7\/01548"],"award-info":[{"award-number":["2016\/21\/D\/NZ7\/01548"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","award":["503\/3-015-01\/503-31-001-19-00"],"award-info":[{"award-number":["503\/3-015-01\/503-31-001-19-00"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","award":["503\/3-015-01\/503-31-004"],"award-info":[{"award-number":["503\/3-015-01\/503-31-004"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejphar.2020.172984","type":"journal-article","created":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T10:59:16Z","timestamp":1580554756000},"page":"172984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["An investigation into the pleiotropic activity of metformin. A glimpse of haemostasis"],"prefix":"10.1016","volume":"872","author":[{"given":"Magdalena","family":"Markowicz-Piasecka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Sadkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiina M.","family":"Huttunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Podsiedlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Mikiciuk-Olasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Sikora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.172984_bib1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.yrtph.2017.12.023","article-title":"A reappraisal on metformin","volume":"92","author":"Adak","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172984_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1155\/2015\/490842","article-title":"GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective","volume":"2015","author":"Adela","year":"2015","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ejphar.2020.172984_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.107.709204","article-title":"Cardiovascular risk factors and venous thromboembolism: a meta-analysis","volume":"117","author":"Ageno","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2020.172984_bib4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.2337\/diab.46.5.860","article-title":"Production of plasminogen activator inhibitor 1 by human adipose tissue, possible link between visceral fat accumulation and vascular disease","volume":"46","author":"Alessi","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2020.172984_bib5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bph.12496","article-title":"Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1","volume":"171","author":"Arunachalam","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172984_bib6","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1007\/s00125-019-4913-2","article-title":"The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study","volume":"62","author":"Au Yeung","year":"2019","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.ejphar.2020.172984_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072120","article-title":"Metformin inhibits angiotensin II-induced differentiation of cardiac fibroblasts into myofibroblasts","volume":"8","author":"Bai","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.172984_bib8","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2020.172984_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms19010293","article-title":"Proangiogenic effect of metformin in endothelial cells is via upregulation of VEGFR1\/2 and their signaling under hyperglycemia-hypoxia","volume":"19","author":"Bakhashab","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2020.172984_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00125-018-4751-7","article-title":"Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malm\u00f6 Diet and Cancer\u2013Cardiovascular Cohort","volume":"62","author":"Bao","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2020.172984_bib11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/01.ATV.17.4.802","article-title":"Megakariocyte ploidy and platelet changes in human diabetes and arteriosclerosis","volume":"17","author":"Brown","year":"1997","journal-title":"Arterioscl. Throm. Vas."},{"key":"10.1016\/j.ejphar.2020.172984_bib12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2337\/dc15-0488","article-title":"The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short- term pharmacokinetic and 12-week dose- ranging studies","volume":"39","author":"Buse","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2020.172984_bib13","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1210\/jc.2004-0019","article-title":"The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial","volume":"89","author":"Caballero","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2020.172984_bib14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/db07-1098","article-title":"Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling","volume":"57","author":"Calvert","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2020.172984_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0168-8227(96)80033-7","article-title":"Oxidative stress and platelet activation in diabetes mellitus","volume":"30","author":"Catella-Lawson","year":"1996","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2020.172984_bib16","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.2337\/diacare.21.11.1967","article-title":"Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity","volume":"21","author":"Charles","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2020.172984_bib17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3892\/ol.2015.2883","article-title":"Effect of metformin on insulin-resistant endothelial cell function","volume":"9","author":"Chen","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejphar.2020.172984_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3904\/kjim.1992.7.2.81","article-title":"Plasma tPA and PAI-1 antigen concentrations in non-insulin dependent diabetic patients, effects of treatment modality on fibrinolysis","volume":"7","author":"Cho","year":"1992","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.ejphar.2020.172984_bib19","first-page":"420","article-title":"Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients","volume":"15","author":"Collier","year":"1989","journal-title":"Diabete Metab."},{"key":"10.1016\/j.ejphar.2020.172984_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00558236","article-title":"The direct effects of metformin on platelet function in vitro","volume":"37","author":"De Caterina","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172984_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/joim.12128","article-title":"Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial","volume":"275","author":"De Jager","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejphar.2020.172984_bib22","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2337\/diabetes.54.7.2179","article-title":"Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process","volume":"54","author":"Detaille","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2020.172984_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3109\/09537104.2012.674165","article-title":"The effect of metformin on mean platelet volume in d\u0131abet\u0131c patients","volume":"24","author":"Dolas\u0131k","year":"2013","journal-title":"Platelets"},{"key":"10.1016\/j.ejphar.2020.172984_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11906-005-0083-3","article-title":"Metabolic syndrome therapy: prevention of vascular injury by antidiabetic agents","volume":"7","author":"Dominguez","year":"2005","journal-title":"Curr. Hyperten. Rep."},{"key":"10.1016\/j.ejphar.2020.172984_bib25","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/bph.13833","article-title":"Activation of AMP-activated protein kinase by metformin ablates angiotensin II-induced endoplasmic reticulum stress and hypertension in mice in vivo","volume":"174","author":"Duan","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172984_bib26","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s11883-013-0314-z","article-title":"Metformin therapy in diabetes: the role of cardioprotection","volume":"15","author":"El Messaoudi","year":"2013","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.ejphar.2020.172984_bib27","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3892\/mmr.2012.753","article-title":"Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cells","volume":"5","author":"Esfahanian","year":"2012","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2020.172984_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0002-9149(03)00616-7","article-title":"Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease","volume":"92","author":"Fonseca","year":"2003","journal-title":"Am. Col. Cardiol."},{"key":"10.1016\/j.ejphar.2020.172984_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/dmrr.794","article-title":"Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects","volume":"24","author":"Formoso","year":"2008","journal-title":"Diabetes-Metab. Res."},{"key":"10.1016\/j.ejphar.2020.172984_bib30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/dmrr.282","article-title":"Metformin decreases platelet superoxide anion production in diabetic patients","volume":"18","author":"Gargiulo","year":"2002","journal-title":"Diabetes-Metab. Res."},{"key":"10.1016\/j.ejphar.2020.172984_bib31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.rbmo.2010.11.006","article-title":"Metformin modulates IL-8, IL-1\u03b2, ICAM and IGFBP-1 expression in human endometrial stromal cells","volume":"22","author":"Germeyer","year":"2011","journal-title":"Reprod. Biomed. Online"},{"key":"10.1016\/j.ejphar.2020.172984_bib32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2337\/dc16-1682","article-title":"Growth differentiation factor 15 as a novel biomarker for metformin","volume":"40","author":"Gerstein","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2020.172984_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejphar.2011.03.029","article-title":"Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats","volume":"659","author":"Ghatak","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172984_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0168-8227(89)90058-2","article-title":"Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics","volume":"6","author":"Gin","year":"1989","journal-title":"Diabetics Res. Clin. Pr."},{"key":"10.1016\/j.ejphar.2020.172984_bib35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1262-3636(07)70064-2","article-title":"Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients","volume":"29","author":"Gin","year":"2003","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ejphar.2020.172984_bib36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1159\/000502257","article-title":"Metformin and aging: a review","volume":"65","author":"Glossmann","year":"2019","journal-title":"Gerontology"},{"key":"10.1016\/j.ejphar.2020.172984_bib37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cca.2013.11.028","article-title":"Acetylsalicylic acid therapy: influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels","volume":"429","author":"Gon\u00e7alves","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejphar.2020.172984_bib38","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2337\/dc07-1569","article-title":"Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men","volume":"31","author":"Goya","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2020.172984_bib39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2337\/diacare.19.1.64","article-title":"The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes","volume":"19","author":"Grant","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2020.172984_bib40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0037-1615172","article-title":"Metformin reduces circulating factor VII concentrations in patients with type 2 diabetes mellitus","volume":"80","author":"Grant","year":"1998","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.ejphar.2020.172984_bib41","doi-asserted-by":"crossref","first-page":"6S44","DOI":"10.1016\/S1262-3636(03)72787-6","article-title":"Beneficial effects of metformin on haemostasis and vascular function in man","volume":"29","author":"Grant","year":"2003","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ejphar.2020.172984_bib42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1464-5491.1991.tb01610.x","article-title":"Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients","volume":"8","author":"Grant","year":"1991","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejphar.2020.172984_bib43","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1046\/j.1464-5491.1999.00201.x","article-title":"Poorly controlled elderly type 2 diabetic patients, the effects of increasing sulphonylurea dosages or adding metformin","volume":"16","author":"Gregorio","year":"1999","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejphar.2020.172984_bib44","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.3760\/cma.j.issn.0366-6999.20132781","article-title":"Metformin inhibits nuclear factor-\u03baB activation and inflammatory cytokines expression induced by high glucose via adenosine monophosphate-activated protein kinase activation in rat glomerular mesangial cells in vitro","volume":"127","author":"Gu","year":"2014","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.ejphar.2020.172984_bib45","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1210\/jcem.86.2.7410","article-title":"Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance","volume":"86","author":"Hadigan","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2020.172984_bib46","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2337\/diabetes.54.5.1566","article-title":"Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. The diabetes prevention program research group","volume":"54","author":"Haffner","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2020.172984_bib47","first-page":"1365","article-title":"Metformin-induced activation of AMPK inhibits the proliferation and migration of human aortic smooth muscle cells through upregulation of p53 and IFI16","volume":"41","author":"Hao","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejphar.2020.172984_bib48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cmet.2015.01.003","article-title":"Metformin action: concentrations matter","volume":"21","author":"He","year":"2015","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejphar.2020.172984_bib49","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1056-8727(02)00282-9","article-title":"Mean platelet volume in type 2 diabetic patients","volume":"18","author":"Hekimsoy","year":"2004","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.ejphar.2020.172984_bib50","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cmet.2016.12.009","article-title":"Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex","volume":"25","author":"Howell","year":"2017","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejphar.2020.172984_bib51","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1021\/jm900274q","article-title":"The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption","volume":"52","author":"Huttunen","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.172984_bib52","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ejps.2013.05.023","article-title":"Convenient microwaveassisted synthesis of lipophilic sulfonamide prodrugs of metformin","volume":"49","author":"Huttunen","year":"2013","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejphar.2020.172984_bib53","first-page":"331","article-title":"Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1","volume":"13","author":"Juhan-Vague","year":"1987","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ejphar.2020.172984_bib54","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40262-015-0323-x","article-title":"Therapeutic concentrations of metformin: a systematic review","volume":"55","author":"Kajbaf","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2020.172984_bib55","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000381643","article-title":"Metformin: an old drug for the treatment of diabetes but a new drug for the protection of the endothelium","volume":"24","author":"Kinaan","year":"2015","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.ejphar.2020.172984_bib56","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2020.172984_bib57","first-page":"403","article-title":"P\u0142ytki krwi w cukrzycy typu 2","volume":"46","author":"Koper","year":"2010","journal-title":"Diagn. Lab."},{"key":"10.1016\/j.ejphar.2020.172984_bib58","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1734-1140(13)70980-0","article-title":"Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance","volume":"65","author":"Krysiak","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2020.172984_bib59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2796.1991.tb00328.x","article-title":"Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors","volume":"229","author":"Landin","year":"1991","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejphar.2020.172984_bib60","article-title":"SHIPping out diabetes-Metformin, an old friend among new SHIP2 inhibitors","volume":"24","author":"Lehtonen","year":"2019","journal-title":"Acta Physiol."},{"key":"10.1016\/j.ejphar.2020.172984_bib61","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2337\/diabetes.54.7.2227","article-title":"Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin inhibitory effect of metformin","volume":"54","author":"Li","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2020.172984_bib62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.20452\/pamw.1201","article-title":"Novel pathway of iron induced blood coagulation: implications for diabetes mellitus and its complications","volume":"122","author":"Lipinski","year":"2012","journal-title":"Pol. Arch. Med. Wewn."},{"key":"10.1016\/j.ejphar.2020.172984_bib63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12974-014-0177-4","article-title":"Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion","volume":"11","author":"Liu","year":"2014","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejphar.2020.172984_bib64","doi-asserted-by":"crossref","first-page":"711","DOI":"10.6061\/clinics\/2012(07)03","article-title":"Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus","volume":"67","author":"Machado","year":"2012","journal-title":"Clinics"},{"key":"10.1016\/j.ejphar.2020.172984_bib65","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejim.2012.10.011","article-title":"Metformin: the hidden chronicles of a magic drug","volume":"24","author":"Mahmood","year":"2013","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ejphar.2020.172984_bib66","doi-asserted-by":"crossref","first-page":"6S71","DOI":"10.1016\/S1262-3636(03)72790-6","article-title":"Antiatherogenic properties of metformin:the experimental evidence","volume":"29","author":"Mamputu","year":"2003","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ejphar.2020.172984_bib67","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.2174\/1381612822666161201152941","article-title":"Is metformin a perfect drug? Updates in pharmacokinetics and pharmacodynamics","volume":"23","author":"Markowicz-Piasecka","year":"2017","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejphar.2020.172984_bib68","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejphar.2017.06.011","article-title":"New prodrugs of metformin do not influence the overall haemostasis potential and integrity of the erythrocyte membrane","volume":"811","author":"Markowicz-Piasecka","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172984_bib69","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cbi.2017.12.005","article-title":"Biocompatible sulfenamide and sulfonamide derivatives of metformin can exert beneficial effects on plasma haemostasis","volume":"280","author":"Markowicz-Piasecka","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejphar.2020.172984_bib70","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cbi.2018.02.012","article-title":"Sulfenamide and sulfonamide derivatives of metformin can exert anticoagulant and profibrinolytic properties","volume":"284","author":"Markowicz-Piasecka","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejphar.2020.172984_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-43083-z","article-title":"Sulfenamide and sulfonamide derivatives of metformin \u2013 a new option to improve endothelial function and plasma haemostasis","volume":"9","author":"Markowicz-Piasecka","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2020.172984_bib72","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bioorg.2019.03.036","article-title":"Sulfenamide derivatives can improve transporter-mediated cellular uptake of metformin and induce cytotoxicity in human breast adenocarcinoma cell lines","volume":"87","author":"Markowicz-Piasecka","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejphar.2020.172984_bib73","first-page":"1029","article-title":"Metformin: an inhibitor of mTORC1 signaling","volume":"2","author":"Melnik","year":"2014","journal-title":"J. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.ejphar.2020.172984_bib75","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2018.07.007","article-title":"Endothelial function and dysfunction: impact of metformin","volume":"192","author":"Nafisa","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2020.172984_bib76","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2337\/diacare.16.4.621","article-title":"Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects","volume":"16","author":"Nagi","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2020.172984_bib77","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/dom.13519","article-title":"Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: a nested, case\u2013control study","volume":"21","author":"Natali","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2020.172984_bib78","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.numecd.2017.04.009","article-title":"Metformin effects on the heart and the cardiovascular system: a review of experimental and clinical data","volume":"27","author":"Nesti","year":"2017","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.ejphar.2020.172984_bib79","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/0953710042000267707","article-title":"Mean platelet volume in patients with type 2 diabetes mellitus","volume":"15","author":"Papanas","year":"2004","journal-title":"Platelets"},{"key":"10.1016\/j.ejphar.2020.172984_bib80","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jdiacomp.2015.04.005","article-title":"Effects of oral hypoglycemic agents on platelet function","volume":"29","author":"Papazafiropoulou","year":"2015","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.ejphar.2020.172984_bib81","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/07853899009147912","article-title":"Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial","volume":"22","author":"Pentikainen","year":"1990","journal-title":"Ann. Med."},{"key":"10.1016\/j.ejphar.2020.172984_bib82","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1002\/jps.24040","article-title":"Sustained release of metformin via red blood cell accumulated sulfenamide prodrug","volume":"106","author":"Peura","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejphar.2020.172984_bib83","doi-asserted-by":"crossref","first-page":"2858\u20102869","DOI":"10.1096\/fj.201800529RR","article-title":"Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity","volume":"33","author":"Polianskyte\u2010Prause","year":"2019","journal-title":"FASEB J"},{"issue":"32","key":"10.1016\/j.ejphar.2020.172984_bib84","doi-asserted-by":"crossref","first-page":"50895","DOI":"10.18632\/oncotarget.10618","article-title":"Viscoelasticity as a measurement of clot structure in poorly controlled type 2 diabetes patients: towards a precision and personalized medicine approach","volume":"7","author":"Pretorius","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2020.172984_bib85","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/01913123.2013.778929","article-title":"Albumin stabilizes fibrin fiber ultrastructure in low serum albumin Type 2 diabetes","volume":"37","author":"Pretorius","year":"2013","journal-title":"Ultrastruct. Pathol."},{"key":"10.1016\/j.ejphar.2020.172984_bib86","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12933-015-0192-5","article-title":"Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombingenerated fibrin: implications for diagnostics","volume":"14","author":"Pretorius","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2020.172984_bib87","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1016\/j.bmcl.2014.09.019","article-title":"Glutathione-S-transferase selective release of metformin from its sulfonamide prodrug","volume":"24","author":"Rautio","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2020.172984_bib88","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/CIRCULATIONAHA.117.031735","article-title":"Repurposing metformin for cardiovascular disease","volume":"137","author":"Rena","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2020.172984_bib89","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ajog.2017.06.003","article-title":"Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity","volume":"217","author":"Romero","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ejphar.2020.172984_bib90","first-page":"259","article-title":"Wp\u0142yw leczenia metformina na wyk\u0142adniki zaburze\u0144 krzepniecia u kobiet z zespo\u0142em policystycznych jajnik\u00f3w i insulinooporno\u015bcia","volume":"82","author":"Serdy\u0144ska Szuster","year":"2011","journal-title":"Ginekol. Pol."},{"key":"10.1016\/j.ejphar.2020.172984_bib91","first-page":"739","article-title":"Mean platelet volume in diabetes mellitus","volume":"86","author":"Sharpe","year":"1993","journal-title":"Q. J. Med."},{"key":"10.1016\/j.ejphar.2020.172984_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4196\/kjpp.2014.18.1.1","article-title":"Advanced glycation end products and diabetic complications","volume":"18","author":"Singh","year":"2014","journal-title":"Korean J. Physiol. Pha."},{"key":"10.1016\/j.ejphar.2020.172984_bib93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1161\/01.ATV.16.1.89","article-title":"Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL","volume":"16","author":"Sironi","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2020.172984_bib94","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1262-3636(03)72794-3","article-title":"The potential of metformin for diabetes Prevention","volume":"29","author":"Slama","year":"2003","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ejphar.2020.172984_bib95","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-015-0261-9","article-title":"Interplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitus","volume":"14","author":"Soma","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2020.172984_bib96","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2337\/diabetes.51.1.189","article-title":"The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerisation and fibrin clot formation","volume":"51","author":"Standeven","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2020.172984_bib97","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2141.2006.06012.x","article-title":"High glucose levels enhance platelet activation: involvement of multiple mechanisms","volume":"133","author":"Sudic","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2020.172984_bib98","first-page":"1049","article-title":"The realtions between platelet count, mean platelet volume and HbA1C in patients with type 2 diabetes","volume":"66","author":"Szeremeta","year":"2009","journal-title":"Przegl. Lek."},{"key":"10.1016\/j.ejphar.2020.172984_bib99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11154-010-9134-4","article-title":"Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications","volume":"11","author":"Tabit","year":"2010","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.ejphar.2020.172984_bib100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1365-2141.1998.00541.x","article-title":"Il- 6 and SCF exert different effects on megakaryocyte maturation","volume":"100","author":"Tajika","year":"1998","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2020.172984_bib101","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bbrc.2013.03.036","article-title":"Metformin induces up-regulation of blood-brain barrier functions by activating AMP-activated protein kinase in rat brain microvascular endothelial cells","volume":"433","author":"Takata","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2020.172984_bib102","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0011-393X(97)80103-8","article-title":"Inhibitory effect of metformin on formation of advanced glycation end products","volume":"56","author":"Tanaka","year":"1997","journal-title":"Curr. Ther. Res."},{"key":"10.1016\/j.ejphar.2020.172984_bib103","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0168-8227(96)01286-7","article-title":"Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus","volume":"33","author":"Testa","year":"1996","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2020.172984_bib104","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/157016112798829760","article-title":"The role of nitric oxide on endothelial function","volume":"10","author":"Tousoulis","year":"2012","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.172984_bib105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0021-9150(82)90069-7","article-title":"Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits","volume":"41","author":"Tremoli","year":"1982","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejphar.2020.172984_bib106","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/apha.12644","article-title":"Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium","volume":"219","author":"Triggle","year":"2017","journal-title":"Acta Physiol."},{"key":"10.1016\/j.ejphar.2020.172984_bib107","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.172984_bib108","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0026-0495(86)90209-X","article-title":"Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects","volume":"35","author":"Vague","year":"1986","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2020.172984_bib109","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1055\/s-0038-1651126","article-title":"Metformin decreases the high plasminogen activator inhibition activity, plasma insulin and triglyceride levels in non-diabetic obese subjects","volume":"57","author":"Vague","year":"1987","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.ejphar.2020.172984_bib110","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/00001721-200110000-00004","article-title":"Comparative study of platelet activation markers in diabetes mellitus patients complicated by cerebrovascular disease","volume":"12","author":"Wang","year":"2001","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.ejphar.2020.172984_bib111","first-page":"42","article-title":"Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus","volume":"57","author":"Watala","year":"2005","journal-title":"Pharm. Rep."},{"key":"10.1016\/j.ejphar.2020.172984_bib112","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/09537109976356","article-title":"Possible mechanisms of the altered platelet volume distribution in type 2 diabetes: does increased platelet activation contribute to platelet size heterogeneity?","volume":"10","author":"Wata\u0142a","year":"1999","journal-title":"Platelets"},{"key":"10.1016\/j.ejphar.2020.172984_bib113","series-title":"Global Report on Diabetes","isbn-type":"print","author":"WHO Report","year":"2016","ISBN":"https:\/\/id.crossref.org\/isbn\/9789241565257"},{"key":"10.1016\/j.ejphar.2020.172984_bib114","first-page":"335","article-title":"Aktywacja p\u0142ytek krwi w zale\u017cno\u015bci od stopnia wyr\u00f3wnania cukrzycy typu 2","volume":"148","author":"Wojszel","year":"2008","journal-title":"Pol. Merkur. Lek."},{"key":"10.1016\/j.ejphar.2020.172984_bib115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/17474124.2017.1273769","article-title":"New insights into the anti-diabetic actions of metformin: from the liver to the gut","volume":"11","author":"Wu","year":"2017","journal-title":"Expet Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2020.172984_bib117","doi-asserted-by":"crossref","DOI":"10.1038\/srep36222","article-title":"Metformin uniquely prevents thrombosis by inhibiting platelet activation and mtDNA release","volume":"6","author":"Xin","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2020.172984_bib118","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1159\/000478068","article-title":"Liver kinase B1\/AMP-activated protein kinase pathway activation attenuated the progression of endotoxemia in the diabetic mice","volume":"42","author":"Yang","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2020.172984_bib119","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lfs.2018.02.017","article-title":"Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses in rabbits","volume":"198","author":"Yang","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2020.172984_bib120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3132\/dvdr.2006.008","article-title":"Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty","volume":"3","author":"Yngen","year":"2006","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.ejphar.2020.172984_bib121","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1464-5491.2005.01765.x","article-title":"Meal-induced platelet activation in type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide","volume":"23","author":"Yngen","year":"2006","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejphar.2020.172984_bib122","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.cmet.2016.09.003","article-title":"Metformin activates AMPK through the lysosomal pathway","volume":"24","author":"Zhang","year":"2016","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejphar.2020.172984_bib123","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1111\/jcmm.13235","article-title":"Metformin ameliorates BSCB disruption by inhibiting neutrophil infiltration and MMP-9 expression but not direct TJ proteins expression regulation","volume":"21","author":"Zhang","year":"2017","journal-title":"J. Cell Mol. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920300765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920300765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:54:54Z","timestamp":1777398894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920300765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":121,"alternative-id":["S0014299920300765"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.172984","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An investigation into the pleiotropic activity of metformin. A glimpse of haemostasis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.172984","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172984"}}